Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers.
作者信息
Visram Alissa, Bredeson Christopher, Allan David, Sabloff Mitchell, Huebsch Lothar, Tay Jason, Kekre Natasha, McDiarmid Sheryl, Mallick Ranjeeta, Tinmouth Alan, Martin Lisa, Hamelin Linda, Maze Dawn
机构信息
Department of Hematology, The Ottawa Hospital, Ottawa, Canada.
Department of Medicine, Calgary, Canada.
出版信息
Blood Cancer J. 2018 Jan 29;8(1):14. doi: 10.1038/s41408-018-0050-2.
Abstract
摘要
相似文献
1
Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers.自体造血细胞移植后的长期移植物功能以及普乐沙福对预测动员效果不佳者的影响。
Blood Cancer J. 2018 Jan 29;8(1):14. doi: 10.1038/s41408-018-0050-2.
2
Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function.在粒细胞集落刺激因子（G-CSF）基础上加用普乐沙福，即使对于动员效果很差的患者也有助于实现有效的采集：给造血功能减退的患者带来了希望。
Bone Marrow Transplant. 2017 Jul;52(7):1049-1050. doi: 10.1038/bmt.2017.80. Epub 2017 May 22.
3
The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest.对于动员效果不佳者，普乐沙福注射液选择在院内给药还是居家给药，对后续造血干细胞采集没有不良影响。
Bone Marrow Transplant. 2017 Aug;52(8):1212-1214. doi: 10.1038/bmt.2017.103. Epub 2017 Jun 5.
4
Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.自体干细胞动员时使用普乐沙福抢救后的患者结局：单中心回顾性分析
Transfusion. 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883. Epub 2016 Nov 18.
5
Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.培洛昔福在自体移植中动员造血干细胞：更新。
Expert Opin Biol Ther. 2014 Jun;14(6):851-61. doi: 10.1517/14712598.2014.902927. Epub 2014 Mar 27.
6
A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.一项针对动员效果不佳的淋巴恶性肿瘤患者使用普乐沙福的全国性调查显示，在法国自体造血干细胞移植项目中，“按需”给药方案得到了广泛应用。
Transfusion. 2015 Sep;55(9):2149-57. doi: 10.1111/trf.13141. Epub 2015 May 13.
7
Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; .在先前进行清髓性大剂量化疗和自体造血干细胞移植后，重新动员造血祖细胞以进行进一步的自体移植。
Leuk Lymphoma. 2019 Jul;60(7):1819-1822. doi: 10.1080/10428194.2018.1543879. Epub 2019 Jan 8.
8
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.使用或不使用普乐沙福动员的非霍奇金淋巴瘤患者的血液移植物细胞组成及移植后恢复：一项前瞻性比较
Transfusion. 2015 Oct;55(10):2358-68. doi: 10.1111/trf.13170. Epub 2015 May 28.
9
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.对于多发性骨髓瘤中干细胞动员效果不佳的患者，普乐沙福无论是作为先发制人的治疗手段还是作为挽救策略使用均有效。
Transfusion. 2015 Feb;55(2):275-83. doi: 10.1111/trf.12813. Epub 2014 Aug 13.
10
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.普乐沙福（莫泽比利）：一种用于预计动员效果不佳的淋巴瘤患者移植的干细胞动员剂——一项试点研究。
Acta Haematol. 2016;135(1):29-36. doi: 10.1159/000435769. Epub 2015 Aug 22.
引用本文的文献
1
The hope, hype and obstacles surrounding cell therapy.细胞治疗的希望、炒作和障碍。
J Cell Mol Med. 2024 May;28(10):e18359. doi: 10.1111/jcmm.18359.
2
Expansion of Haematopoietic Stem and Progenitor Cells: Paving the Way for Next-Generation Haematopoietic Stem Cell Transplantation.造血干细胞和祖细胞的扩增：为下一代造血干细胞移植铺平道路。
Blood Cell Ther. 2019 Nov 25;2(4):58-67. doi: 10.31547/bct-2019-004.
3
Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis.对于动员效果不佳的患者，使用非格司亭生物类似药和普乐沙福将造血干细胞动员至外周血用于自体移植似乎效果较差：一项回顾性比较分析。
Oncol Ther. 2020 Dec;8(2):311-324. doi: 10.1007/s40487-020-00115-3. Epub 2020 May 14.
本文引用的文献
1
Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.使用改良的目标值定制方法改善外周血造血祖细胞采集前CD34+细胞产量的预测
Biol Blood Marrow Transplant. 2016 Apr;22(4):763-767. doi: 10.1016/j.bbmt.2015.11.016. Epub 2015 Nov 28.
2
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.使用或不使用普乐沙福动员的非霍奇金淋巴瘤患者的血液移植物细胞组成及移植后恢复：一项前瞻性比较
Transfusion. 2015 Oct;55(10):2358-68. doi: 10.1111/trf.13170. Epub 2015 May 28.
3
Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.动员的外周血移植物包含的不仅仅是造血干细胞：免疫学视角
Bone Marrow Transplant. 2015 Jul;50(7):886-91. doi: 10.1038/bmt.2014.330. Epub 2015 Feb 9.
4
A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.基于普乐沙福的策略可使动员不佳者获得足够的造血干细胞采集量：来自加拿大特殊准入计划的结果。
Bone Marrow Transplant. 2014 Jun;49(6):751-5. doi: 10.1038/bmt.2014.33. Epub 2014 Mar 10.
5
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.优化自体干细胞动员策略以改善患者结局：共识指南和建议。
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.
6
Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.培门冬酶动员的非霍奇金淋巴瘤患者自体干细胞移植后的植入和结果。
Transfusion. 2014 May;54(5):1243-50. doi: 10.1111/trf.12434. Epub 2013 Sep 30.
7
Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone.粒细胞集落刺激因子和培哚普利奥联合动员与单独使用粒细胞集落刺激因子对周围血干细胞移植物的特征分析。
Cytotherapy. 2013 Jul;15(7):861-8. doi: 10.1016/j.jcyt.2013.03.013.
8
Blood graft composition after plerixafor injection in patients with NHL.非霍奇金淋巴瘤患者注射plerixafor 后的血液移植物成分。
Eur J Haematol. 2012 Aug;89(2):128-35. doi: 10.1111/j.1600-0609.2012.01794.x. Epub 2012 May 24.
9
Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.在动员不佳的淋巴瘤和骨髓瘤患者中，使用普乐沙福和粒细胞集落刺激因子进行充分外周血干细胞动员后自体干细胞移植的长期结果。
Adv Hematol. 2011;2011:517561. doi: 10.1155/2011/517561. Epub 2011 Nov 29.
10
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.CD34细胞剂量对508例接受自体外周血干细胞移植的多发性骨髓瘤患者造血重建及预后的影响。
Eur J Haematol. 2007 Jan;78(1):21-8. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2895.x. Epub 2006 Sep 28.
Zotero 插件